Your browser doesn't support javascript.
loading
Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis.
Vuyyuru, Sudheer K; Kedia, Saurabh; Kalaivani, Mani; Sahu, Pabitra; Kante, Bhaskar; Kumar, Peeyush; Ranjan, Mukesh K; Makharia, Govind; Ananthakrishnan, Ashwin; Ahuja, Vineet.
Afiliación
  • Vuyyuru SK; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Kedia S; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Kalaivani M; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Sahu P; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Kante B; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Kumar P; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Ranjan MK; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Makharia G; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Ananthakrishnan A; Division of Gastroenterology, Massachusetts General Hospital & Harvard Medical School, Boston, MA 02114, USA.
  • Ahuja V; Department of Gastroenterology & Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110029, India.
Future Microbiol ; 16: 1215-1227, 2021 10.
Article en En | MEDLINE | ID: mdl-34590904
Aim: We conducted this network meta-analysis to compare the efficacy and safety of targeted pharmacotherapies and fecal microbial transplantation (FMT). Patients & methods: Nineteen studies were included and there was only one head-to-head randomized controlled trial (adalimumab vs vedolizumab). Results: All interventions, including FMT, were superior to a placebo in inducing clinical remission (except adalimumab - odds ratio 1.66; 95% CI: 0.97-2.85), clinical response and endoscopic remission. FMT was comparable with other agents in achieving all efficacy outcomes. Infliximab was ranked highest in inducing clinical remission (surface under the cumulative ranking, 0.8). There was no difference in safety outcomes between FMT and other targeted therapies. Conclusion: FMT is as efficacious and as safe as other targeted therapies in inducing clinical remission, clinical response and endoscopic remission. Further studies to assess the long-term benefits are needed in order to reach a definitive conclusion.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Trasplante de Microbiota Fecal Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Future Microbiol Asunto de la revista: MICROBIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Trasplante de Microbiota Fecal Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Future Microbiol Asunto de la revista: MICROBIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: Reino Unido